Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review
Colorectal cancer (CRC) continues to be one of the most prevalent and deadliest forms of cancer worldwide, despite notable advancements in its management. The prognosis for metastatic CRC remains discouraging, with a relative 5 -year survival rate for stage IV CRC patients. Conventional treatments f...
Published in: | INTERNATIONAL JOURNAL OF PHARMACEUTICS |
---|---|
Main Authors: | , , , , , , , , |
Format: | Review; Early Access |
Language: | English |
Published: |
ELSEVIER
2024
|
Subjects: | |
Online Access: | https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001154098500001 |
author |
Ibrahim Intan Shazleen; Chellathurai Melbha Starlin; Mahmood Syed; Azmi Amirul Hakim; Harun Norsyifa; Nazri Mohd Ulul Ilmie Ahmad; Mahat Mohd Muzamir; Sofian Zarif Mohamed |
---|---|
spellingShingle |
Ibrahim Intan Shazleen; Chellathurai Melbha Starlin; Mahmood Syed; Azmi Amirul Hakim; Harun Norsyifa; Nazri Mohd Ulul Ilmie Ahmad; Mahat Mohd Muzamir; Sofian Zarif Mohamed Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review Pharmacology & Pharmacy |
author_facet |
Ibrahim Intan Shazleen; Chellathurai Melbha Starlin; Mahmood Syed; Azmi Amirul Hakim; Harun Norsyifa; Nazri Mohd Ulul Ilmie Ahmad; Mahat Mohd Muzamir; Sofian Zarif Mohamed |
author_sort |
Ibrahim |
spelling |
Ibrahim, Intan Shazleen; Chellathurai, Melbha Starlin; Mahmood, Syed; Azmi, Amirul Hakim; Harun, Norsyifa; Nazri, Mohd Ulul Ilmie Ahmad; Mahat, Mohd Muzamir; Sofian, Zarif Mohamed Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review INTERNATIONAL JOURNAL OF PHARMACEUTICS English Review; Early Access Colorectal cancer (CRC) continues to be one of the most prevalent and deadliest forms of cancer worldwide, despite notable advancements in its management. The prognosis for metastatic CRC remains discouraging, with a relative 5 -year survival rate for stage IV CRC patients. Conventional treatments for advanced malignancies such as chemotherapy, often face limitations in effectively targeting cancer cells resulting in off -target distribution and significant side effects. In the quest for better strategies, researchers have explored numerous alternatives. Among these, nanoparticles (NPs) specifically liposomes have emerged as one of the most promising candidates in developing targeted delivery systems for cancer therapeutics. This review discusses the current approaches employing functionalised liposomes to overcome major biological barriers in therapeutics delivery for CRC treatment. We have also shared our perspectives on the technological development of liposomes for future clinical use and highlighted a few useful insights on the material choices for future research work in CRC. ELSEVIER 0378-5173 1873-3476 2024 651 10.1016/j.ijpharm.2023.123735 Pharmacology & Pharmacy WOS:001154098500001 https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001154098500001 |
title |
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review |
title_short |
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review |
title_full |
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review |
title_fullStr |
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review |
title_full_unstemmed |
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review |
title_sort |
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review |
container_title |
INTERNATIONAL JOURNAL OF PHARMACEUTICS |
language |
English |
format |
Review; Early Access |
description |
Colorectal cancer (CRC) continues to be one of the most prevalent and deadliest forms of cancer worldwide, despite notable advancements in its management. The prognosis for metastatic CRC remains discouraging, with a relative 5 -year survival rate for stage IV CRC patients. Conventional treatments for advanced malignancies such as chemotherapy, often face limitations in effectively targeting cancer cells resulting in off -target distribution and significant side effects. In the quest for better strategies, researchers have explored numerous alternatives. Among these, nanoparticles (NPs) specifically liposomes have emerged as one of the most promising candidates in developing targeted delivery systems for cancer therapeutics. This review discusses the current approaches employing functionalised liposomes to overcome major biological barriers in therapeutics delivery for CRC treatment. We have also shared our perspectives on the technological development of liposomes for future clinical use and highlighted a few useful insights on the material choices for future research work in CRC. |
publisher |
ELSEVIER |
issn |
0378-5173 1873-3476 |
publishDate |
2024 |
container_volume |
651 |
container_issue |
|
doi_str_mv |
10.1016/j.ijpharm.2023.123735 |
topic |
Pharmacology & Pharmacy |
topic_facet |
Pharmacology & Pharmacy |
accesstype |
|
id |
WOS:001154098500001 |
url |
https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001154098500001 |
record_format |
wos |
collection |
Web of Science (WoS) |
_version_ |
1809678633513517056 |